Drug news
Kalbitor (Dyax/Defiante Farma) is withdrawn from EMA for acute Hereditary Angioedema
Kalbitor from Dyax Corporation and Defiante Farmaceutica S.A. is withdrawn from its application to the EMA for the treatment of acute attacks of Hereditary Angioedema in patients 16 years and older. The CHMP had required further data. The drug is approved for the indication in the USA.